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INTRODUCTION
The term Systemic sclerosis, or scleroderma, designates a heterogeneous autoimmune connective tissue disease characterized by distinct clinical patterns, which often display dramatically different clinical outcomes as different as a long survival time with limited morbidity and a decreased lifespan with huge disability [1] . One of the main limitations in the clinical management of SSc patients, once diagnosis has been formulated, is the lack of biomarkers predicting disease evolution and correlating with disease activity and severity. In fact, currently available biomarkers are certainly useful for SSc diagnosis, sub-classification and association with organ involvement [2] , but none of them is sensitive to disease changes. To fill this gap, our group has focused the attention on serum anti-PDGFRα autoantibodies characterized by possessing stimulatory activity, both in vitro on human cells involved in SSc pathogenesis [3, 4] and in vivo on regenerated human skin engrafted onto mice [5] , under the hypothesis that biologically active autoantibodies may correlate better with disease activity. One major problem with the validation of this hypothesis was the inability of detecting serum anti-PDGFRα antibodies with standard methods [6] [7] [8] . Recently, this problem has been partly solved by identifying the PDGFRα epitopes bound by these autoantibodies.
We discovered that distinct PDGFRα epitopes are recognized by agonistic and non-agonistic autoantibodies, and used the peptides corresponding to these epitopes to detect the presence of agonistic autoantibodies in the serum of SSc patients but not in healthy controls [9] . However, this method, a competitive ELISA based on molar excess of soluble peptides added to serum samples before PDGFRα binding detection, does not permit quantification of SSc antibodies, limiting their potential as biomarkers usable to dissect the different clinical phases of this chronic disease. To address this issue, we adapted our previously described PDGFRα biosensor [10] to measure and compare the reactivity of agonistic and non-agonistic human anti-PDGFRα autoantibodies cloned from SSc B cells, and applied the binding kinetics of the monoclonal antibody possessing higher M A N U S C R I P T
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4 agonistic activity towards the PDGFRα to calibrate the biosensor, eventually developing a quantitative biosensor-based assay. We describe herein this analytical method able to rapidly and reliably detect and quantify anti-PDGFRα serum IgG autoantibodies with nanomolar sensitivity.
MATERIALS AND METHODS
Materials and devices
CuSO 4 , HCl, NaOH, NaCl, KCl, NaH 2 PO 4 were obtained from Mallinckrodt Baker (Milan, Italy).
Tween-20, G 418 disulphate salt and SDS were from Sigma-Aldrich (Milan, Italy). Carboxylatefunctionalized cuvettes and the immobilization chemicals (N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), and ethanolamine) were obtained from Neosensors (Crewe, UK). All chemicals were of highest purity available. Human PDGFRα and recombinant human monoclonal autoantibodies (mAb), namely V H PAM-
, and V H PAM-V λ 13B8) were produced and purified as previously reported [9, 11] .
Binding analyses were carried out on an evanescent wave/resonant mirror [12] optical biosensor (IAsys plus -Affinity Sensors Ltd, Cambridge, UK). The resonant mirror apparatus (consisting of a high-refractive-index dielectric coupling layer deposited on a silica glass prism waveguide [13] , with a low-refractive-index hafnium oxide layer interposed) is integrated in an open two-wells cuvette structure, with the sensing surface being exposed to the solution contained within the M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 cuvette lumen. Soluble ligands, reagents and buffers can be added by manual pipetting, and removed using an integrated vacuum aspiration system. A micro-stirrer is included to ensure rapid sample mixing and to prevent limits due to diffusion.
Chromatographic analyses were performed on an AKTA Basic System (GE Healthcare, Milan, Italy), using HiTrap metal-chelating columns obtained from GE Healthcare (Milan, Italy), and a Tosoh Progel TM -TSK G2000 SWXL column, 30 cm × 7.8 mm (Sigma Aldrich, Milan, Italy).
Immobilization of rhPDGFRα-His
rhPDGFRα-functionalized surfaces were obtained as previously reported [10] . Briefly, carboxylate cuvettes were rinsed with PBS pH 7.4, and activated with an equimolar solution of EDC and NHS [14] . rhPDGFRα-His was solubilized in 10 mM CH 3 COONa buffer pH 4.5, then anchored to the carboxylic surface via the N-terminus of histidine tail. To achieve optimal surface density, we tested different rhPDGFRα concentrations in the range 100-800 µg/mL: the concentration 300 µg/mL was finally selected as it provided an adequate number of binding sites, and at the same time prevented the dimerization between blocked rhPDGFRα macromolecules that could reduce the number of available binding sites on the sensing surface [9] . In detail, 100, 200 and 800 µg/mL rhPDGFRα solutions yielded to surfaces with lower sensibility (rhPDGFRα surface resulting from 100 and 200 µg/mL solutions was characterized by lower surface density/number of binding sites for SSc autoantibodies; rhPDGFRα surface resulting from 800 µg/mL solution, irrespective of higher surface density, was characterized by a lower number of effectively available binding for SSc autoantibodies, both because of steric hindrance and rhPDGFRα dimerization). Next, free carboxylic sites on the sensor surface were blocked by injection of 1 M ethanolamine, pH 8. significantly improve the quality of the fit as judged by an F-test, 95% confidence). The biosensor chamber was thermostatted at 25°C throughout.
Derivation of binding kinetics of PDGF-BB to rhPDGFRα-functionalized surface
Kinetic parameters of the interaction between PDGF-BB and rhPDGFRα were determined by individual additions of 0.13, 0.26, 1.33 and 2.66 nM PDGF-BB (three replicates each). Association kinetics were followed for about 1 min (the time interval requested to reach the maximal response at equilibrium for the highest concentration of PDGF-BB tested). The dissociation of each complex was achieved with a single PBS (pH=7.4) wash (dissociation phases were followed for 1 min),
whereas baseline recovery (regeneration of non-complexed rhPDGFRα surface) was obtained with multiple PBS (pH 5.5). Regeneration procedure times ranged between 5 and 15 min, depending upon PDGF-BB concentration.
Binding of recombinant human mAbs to rhPDGFRα-functionalized surface
Recombinant human mAbs were independently added at different concentrations in the range 0.58-16 nM onto the rhPDGFRα-coated surface, and association kinetics were routinely followed up to equilibrium. Dissociation steps and surface regeneration were performed by addition of fresh buffer (PBS pH=7.4 and pH=5.5, respectively), each time assessing the baseline recovery prior to any further addition of soluble recombinant human mAbs. Raw data were globally fitted to a classic monophasic model:
where R t is the response at time t,
R max is the maximal response at asymptotically high concentrations of [recombinant human mAb], and k ass and k diss are the kinetic association and dissociation constants, respectively. Data analysis and fitting was performed with FAST Fit software. Table 1 . All participants gave informed consent for use of blood samples in this study. Ethics committee approval document is provided as Supplemental Material. Table 1 . Clinical characteristics of SSc patients.
Serum samples
Purification of IgG from serum
IgG were purified from the SSc and HC sera, selected as indicated above, using individual A/G resin columns (Pierce) as previously described [10] . After elution with glycine at pH 2. 
Binding of serum IgG to rhPDGFRα-functionalized biosensor
IgG samples were individually added to the PDGFRα-functionalized surface, and each response kinetic was monitored up to equilibrium. The dissociation of the complexes and the regeneration of the PDGFRα monolayer were carried out by serial PBS washes. Each IgG sample was analysed in triplicate. Values falling outside the 95% confidence interval were considered significantly different from controls. Detection procedures were replicated on different days (n=3) both on the same and on different rhPDGFRα-functionalized surfaces (n=3) to assess the inter-day and the "surface-tosurface" variability. Analyses of SSc IgG samples were always performed in triplicate.
Additionally, the number of regeneration cycles that the sensor surface could withstand without significant loss of assay sensitivity and accuracy, and the stability of the sensing surface throughout multiple measurements were evaluated and assessed.
Immunoenzymatic assays (ELISAs)
All IgG samples were tested by direct and competitive anti-PDGFRα antibody ELISA as previously described [9] . A standard hyperbolic calibration curve was used to estimate the concentration of anti-PDGFRα antibody from absorbance units.
Limits of Detection and Quantitation
In compliance with the IUPAC rules [16] , the limits of detection (LOD) and quantification (LOQ)
of both ELISA and biosensor assays were calculated as three and ten times the standard deviation of the blank measurements, respectively. IgG purified from HC sera were used as a blank reference. 
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Binding kinetics and binding specificity of recombinant human mAbs
First, we characterized the binding of recombinant human mAbs [9] to surface-blocked rhPDGFRα, whose native-like folding was assessed by conformational ligands, as described in the Material and
Methods section (Fig.1, Panel A) . immobilized human PDGFRβ-His. The recombinant human mAbs, either used at the same concentration or six-fold higher, did not bind to natively folded PDGFRβ (data not shown).
Calibration Curve
Based on the high affinity for rhPDGFRα and the better confidence limits for dose-response curve compared with the other anti-PDGFRα recombinant human mAbs (as assessed by Student's t-test applied at 95% confidence level), V H PAM-V κ 16F4 was chosen to generate a calibration curve.
Thus, V H PAM-V κ 16F4 was added to the surface-immobilized PDGFRα-His at different concentrations in the range 1-10 nM (Fig.3) , and association kinetics were monitored up to equilibrium (R eq ). The plot of R eq versus V H PAM-V κ 16F4 concentration showed the hyperbolic correlation:
where R max is the response at asymptotically high concentrations of the autoantibody. This calibration procedure was replicated on three different days. Under the experimental conditions Calibration data were expressed throughout as equivalents of V H PAM-V κ 16F4 per litre. 
Quantification of anti-PDGFRα antibodies in IgG purified from serum
Different dilutions of IgG samples were evaluated to minimize background signal due to crossreactivity with non-SSc IgGs and decrease the biosensor response within the calibration range. 1:8 dilution of IgG samples in PBS buffer was adopted throughout. Additionally, lower dilution factors were excluded as they were associated to lower discriminating ability among different SSc samples:
in fact, the levels of anti-PDGFRα IgG in non-diluted, 1:2 and 1:4 diluted samples were closer to saturating values for rhPDGFRα surface (corresponding to regions of the calibration curve with lower slope). Moreover, the 1:8 dilution was critical in reducing the time requested for surface regeneration (under the adopted dilution, regeneration procedures required less than 15 min).
Limits of detection (LOD) and quantification (LOQ) of the proposed biosensor for anti-PDGFRα
IgG (calculated as described in the Materials and Methods Section) were 2.18 and 3.08
For each IgG sample, three replicates were independently tested, and each sample was analysed in triplicate. Using the V H PAM-V κ 16F4 calibration curve, it was possible to detect and quantify anti-PDGFRα IgG in all the 8 SSc IgG samples (3.24-4.72 neq/L range) (Table 2A) . SSc7 was the only sample being on the edge of significant difference from LOQ, whereas all IgG samples from other patients were significantly higher than LOQ.
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Conversely, only 1 out of 8 HC IgG was positive for anti-PDGFRα IgG, but under the quantification threshold of the biosensor (Table 2B ).
Due to the small number of samples, all intentionally selected among patients with a more severe disease phenotype, any statistical comparison was of limited utility. Nevertheless, two major subgroups with statistically different SSc IgG content were identified (Group 1: SSc2, SSc4, SSc5 and SSc7; Group 2: SSc1, SSc3, SSc6 and SSc8). Concerning intra-group comparison, non-significant differences were observed in SSc IgG content among patients SSc1, SSc3, and SSc8. Additionally, SSc8 was not statistically different from SSc6. No significant difference was observed among SSc2, SSc4, SSc5 and SSc7.
Correlation between biosensor and ELISA data
The same IgG preparations were also tested by ELISA, both in the direct and in the competitive formats previously reported [9] .
Comparative analysis revealed the lower sensibility of the direct ELISA: in fact, using the V H PAM- On the other hand, all the 8 HC IgG samples were double negative, except for HC 3 and 8 that tested positive by direct but not by competitive ELISA (Table 2B ); interestingly, HC3 tested positive also by biosensor assay.
Reusability and efficiency of the biosensor
Different regeneration conditions were tested. The complete dissociation of the recombinant human mAb/rhPDGFRα complexes was performed by washes with both mild acidic (HCl 10 mM) and with buffer solutions (the PBS binding buffer, with pH set to 5.5). Using 10 mM HCl, the biosensor surface could be used without any loss of activity for at least 10 measurement cycles before significant loss of binding capacity was reported. Conversely, the sensing surface resisted to a higher number of experimental cycles (biosensor response did not change by more than 5% after 50 regeneration cycles) when PBS pH=5. Concerning the inter-day variation of the same surface, the maximal coefficients of variation (5.1% at 10 nM V H PAM-V κ 16F4, and 4.1% at 1 nM V H PAM-V κ 16F4, respectively) were within the confidence limits of the calibration curve.
Additionally, the "surface-to-surface" variation of assay sensitivity was assessed by comparing the 
Discussion
One of the major advantages of biosensors lies in their versatility, as they can be customized and efficiently used in a wide range of applications [17] [18] [19] [20] . Specifically, biosensors (both re-usable and single-use) are gaining an increasing impact on clinical chemistry and diagnosis [21] [22] [23] [24] [25] [26] .
Under optimized experimental conditions [10] , here we characterized the binding kinetics of a unique panel of recombinant human monoclonal autoantibodies with different PDGFRα epitope specificity and biological activity [9, 11] . Tested autoantibodies showed strong specificity (PDGFRβ was not recognized) as well as moderate-to-high affinity for PDGFRα. Interestingly, we observed an affinity range progressively increasing from the non-agonistic antibody V H PAM-V κ 13B8 to the native ligand PDGF-BB, and we found that V H PAM-V κ 16F4 agonistic antibody, binding specifically to a conformational motif of the human PDGFRα largely overlapping with the PDGF-BB binding site [9] , possessed the binding profile most similar to PDGF-BB. Based on these results, V H PAM-V κ 16F4 mAb was used to calibrate the biosensor for the selective detection and quantification of human PDGFRα-specific, high affinity, bona fide agonistic, serum IgG autoantibodies, like those expected to be enriched in patients affected by SSc [3] . For biosensor analysis, we employed IgG purified from serum, since whole serum generated an extremely high, an alternative tool when screening samples for agonistic anti-PDGFRα autoantibodies only. For the latter aim, the biosensor seems to be better suited than the competitive ELISA previously described, not only for the higher sensitivity but also for the shorter assay time, the lower consumption of reagents, and the lower cost per single analysis (Table 3 ). In fact, the competitive ELISA is characterized by an additional step consisting in the sample pre-incubation with a soluble peptide, with subsequent problems in terms of assay standardization and rapidity. Nonetheless, the real-time monitoring of biosensor response allows to check proper folding/orientation of rhPDGFRα upon immobilization. Table 3 . Comparison of costs and time associated with (direct and competitive) ELISA and the proposed biosensor assay (*overnight incubation required; ** two-overnight incubation required).
Moreover, the interpretation of the ELISA data requires a not trivial analytical step consisting in the determination of the optimal cut-off value by ROC curve. Conversely, the biosensor provides unambiguous responses upon the binding of high affinity anti-PDGFRα antibodies within one minute. Thus, it is possible to perform a quick screening of multiple samples (collectively requiring about one hour for the purification of IgG from serum).
Besides these aspects, the biosensor assay holds another major advantage towards the ELISA, that is the quantification ability. This feature is relevant for an assay designed to measure the levels of M A N U S C R I P T
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autoantibodies in human samples as biomarkers of SSc disease. In point of fact, we intentionally selected for this study 8 serum/IgG samples taken from patients with a more severe disease phenotype, in order to test the ability of our method to detect and measure anti-PDGFRα antibody levels in those patients who in real life would benefit from a quantifiable biomarker, e.g. during therapy. Of course, it will be mandatory applying this novel biosensor assay to samples taken from patients at different stages of disease to assess if high affinity anti-PDGFRα antibodies are sensitive to disease change and are, therefore, suitable as SSc biomarkers. This would fill an important gap in the current management of different SSc patients' subsets [27] . 
HIGHLIGHTS
A platelet-derived growth factor receptor α-based biosensor is presented.
High-affinity specific interactions are observed between surface-blocked receptor and autoantibodies.
The biosensor can detect and quantify high-affinity anti-PDGFRα autoantibodies in total serum IgG, thus discriminating SSc patients from healthy controls.
